Literature DB >> 21779956

Risk evaluation, prophylaxis, and treatment of tumor lysis syndrome: consensus of an Italian expert panel.

Andrea Pession1, Riccardo Masetti, Gianluca Gaidano, Patrizia Tosi, Giovanni Rosti, Massimo Aglietta, Giorgina Specchia, Fulvio Porta, Fabrizio Pane.   

Abstract

INTRODUCTION: Tumor lysis syndrome (TLS) is a life-threatening complication in patients with hematological disease and/or solid tumors that results from rapid, large-scale tumor necrosis occurring spontaneously, or more commonly, as a result of chemotherapy. TLS is characterized by metabolic and electrolyte imbalances that include hyperuricemia, hyperkalemia, hyperphosphatemia, and hypocalcemia. Identification of risk groups as well as early detection of TLS is crucial for the establishment of appropriate strategies of prophylaxis and treatment.
METHODS: A review of the peer-reviewed literature on TLS between 1990 and 2011 was conducted via a systematic search of the PubMed database using the keywords "TLS" [AND] "management," "risk evaluation," "prophylaxis," and "treatment." An expert opinion-based approach was used to review the national and international recommendations and guidelines on the topic.
RESULTS: The PubMed search produced 90 results, all of which were evaluated. These studies, together with a recent international consensus panel provided recommendations for evaluating the risk of TLS and providing prophylaxis. Five algorithms are presented that consider all of the factors when assessing the risk for neoplastic disease in general, and specifically for leukemia and lymphoma.
CONCLUSION: The present report provides clinicians with an easily consultable tool to guide the evidence-based management of this oncohematological emergency.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21779956     DOI: 10.1007/s12325-011-0041-1

Source DB:  PubMed          Journal:  Adv Ther        ISSN: 0741-238X            Impact factor:   3.845


  5 in total

Review 1.  Management of Hyperleukocytosis.

Authors:  Antonio Ruggiero; Daniela Rizzo; Maria Amato; Riccardo Riccardi
Journal:  Curr Treat Options Oncol       Date:  2016-02

2.  Hypouricemic effect and safety of febuxostat used for prevention of tumor lysis syndrome.

Authors:  Koichiro Maie; Yasuhisa Yokoyama; Naoki Kurita; Hideto Minohara; Shintaro Yanagimoto; Yuichi Hasegawa; Masato Homma; Shigeru Chiba
Journal:  Springerplus       Date:  2014-09-05

3.  Tumour lysis syndrome: A rare acute presentation of locally advanced testicular cancer - Case report and review of literature.

Authors:  Marcus Chow; Arianto Yuwono; Ronny Tan
Journal:  Asian J Urol       Date:  2015-10-24

4.  Letter to the editor.

Authors:  Vito D'Alessandro; Mario Greco
Journal:  J Blood Med       Date:  2012-08-03

Review 5.  Prevention and management of tumor lysis syndrome in adults with malignancy.

Authors:  Jessica Sarno
Journal:  J Adv Pract Oncol       Date:  2013-03
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.